These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20034362)

  • 1. Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease.
    Fassett RG; Coombes JS; Packham D; Fairley KF; Kincaid-Smith P
    Scand J Urol Nephrol; 2010 Feb; 44(1):56-61. PubMed ID: 20034362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.
    Cadnapaphornchai MA; George DM; McFann K; Wang W; Gitomer B; Strain JD; Schrier RW
    Clin J Am Soc Nephrol; 2014 May; 9(5):889-96. PubMed ID: 24721893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.
    Klawitter J; McFann K; Pennington AT; Wang W; Klawitter J; Christians U; Schrier RW; Gitomer B; Cadnapaphornchai MA
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1534-41. PubMed ID: 26224879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
    Atthobari J; Brantsma AH; Gansevoort RT; Visser ST; Asselbergs FW; van Gilst WH; de Jong PE; de Jong-van den Berg LT;
    Nephrol Dial Transplant; 2006 Nov; 21(11):3106-14. PubMed ID: 16720593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
    Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
    Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease.
    Serra AL; Kistler AD; Poster D; Krauer F; Senn O; Raina S; Pavik I; Rentsch K; Regeniter A; Weishaupt D; Wüthrich RP
    Nephrol Dial Transplant; 2009 Nov; 24(11):3334-42. PubMed ID: 19525519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics.
    Gitomer BY; Wang W; George D; Coleman E; Nowak KL; Struemph T; Cadnapaphornchai MA; Patel NU; Jovanovich A; Klawitter J; Farmer B; Ostrow A; You Z; Chonchol M
    Contemp Clin Trials; 2024 Feb; 137():107423. PubMed ID: 38151173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal response to prostaglandin E1 infusion in polycystic kidney disease versus non-polycystic renal disease.
    Uemasu J; Munemura C; Fujihara M; Kawasaki H
    Clin Nephrol; 1995 Oct; 44(4):225-30. PubMed ID: 8575121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin-induced arrest in progression of renal disease.
    Vidt DG; Cressman MD; Harris S; Pears JS; Hutchinson HG
    Cardiology; 2004; 102(1):52-60. PubMed ID: 15073451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.
    Cadnapaphornchai MA; George DM; Masoumi A; McFann K; Strain JD; Schrier RW
    Contemp Clin Trials; 2011 May; 32(3):437-45. PubMed ID: 21266204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD.
    Higashihara E; Nutahara K; Horie S; Muto S; Hosoya T; Hanaoka K; Tuchiya K; Kamura K; Takaichi K; Ubara Y; Itomura M; Hamazaki T
    Nephrol Dial Transplant; 2008 Sep; 23(9):2847-52. PubMed ID: 18372389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
    Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
    Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
    Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
    Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in patients with autosomal dominant polycystic kidney disease.
    Walz G; Budde K; Mannaa M; Nürnberger J; Wanner C; Sommerer C; Kunzendorf U; Banas B; Hörl WH; Obermüller N; Arns W; Pavenstädt H; Gaedeke J; Büchert M; May C; Gschaidmeier H; Kramer S; Eckardt KU
    N Engl J Med; 2010 Aug; 363(9):830-40. PubMed ID: 20581392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion.
    Joyce M; Kelly C; Winter D; Chen G; Leahy A; Bouchier-Hayes D
    J Surg Res; 2001 Nov; 101(1):79-84. PubMed ID: 11676559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine.
    Gronwald W; Klein MS; Zeltner R; Schulze BD; Reinhold SW; Deutschmann M; Immervoll AK; Böger CA; Banas B; Eckardt KU; Oefner PJ
    Kidney Int; 2011 Jun; 79(11):1244-53. PubMed ID: 21389975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.